Peritoneal dialysis  by Chaimovitz, Cidio
Kidney International, Vol. 45 (1994), pp. 1226—1240
NEPHROLOGY FORUM
Peritoneal dialysis
Principal discussant: CIDI0 CHAIM0vITz
Soroka Medical Center of Kupat Holim, Ben Gurion University of the Negev Center for Health Sciences, Beer-S heva, Israel
A 46-year-old man with end-stage renal failure due to polycystic
kidney disease, who had been treated by continuous ambulatory
peritoneal dialysis (CAPD) for 33 months, was admitted to the Soroka
Medical Center because of 2 hours of fever, abdominal pain, nausea,
and cloudy peritoneal fluid. On physical examination he appeared
uncomfortable and complained of severe abdominal pain. His temper-
ature was 39°C; pulse, 108 beats/mm; and respirations, 24 breaths/mm.
The blood pressure was 150/95 mm Hg. The lungs were clear; the heart
rhythm was regular, and an apical grade-2 holosystolic murmur was
audible. Abdominal examination disclosed diminished bowel sounds
and diffuse abdominal tenderness. The exit site of the Tenckhoff
catheter was normal. The lower extremities were normal and peripheral
pulses were intact. The peritoneal effluent was very cloudy and con-
tained 7000 cells/mm3, of which 95% were polymorphonuclear leuko-
cytes. The patient was treated initially with a combination of intraperi-
toneal vancomycin and aminoglycoside. Dialysate cultures grew
Staphylococcus aureus and rifampin was added to the treatment. The
peritoneal dialysate gradually cleared, but the patient continued to have
fever and severe abdominal pain for 5 days, and the dialysate culture
became negative only after 7 days of treatment.
Until his latest admission, the patient's fluid balance, nutrition, and
biochemical values had been well controlled. He had been treated with
four peritoneal exchanges daily; three changes were performed with
peritoneal dialysis solutions containing 1.5% glucose and the fourth
with 2.5%. The calcium concentration of the dialysis solution was 2.5
mEq/liter. He received 600 mg calcium carbonate 3 times/day during
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meals, 0.25 pg/day of vitamin D3, and subcutaneously administered
erythropoietin, 4000 U/week. The patient's weekly combined creatinine
clearance (renal and peritoneal clearance) was 60 liters. Laboratory
tests one month before the episode of peritonitis showed a BUN of 64
mg/dl; serum creatinine, 9.2 mg/dl; uric acid, 8.7 mg/dl; sodium, 138
mEq/liter; potassium, 4.3 mEq/liter; calcium, 10.3 mg/dl; phosphorus,
5.3 mg/dl; albumin, 3.8 g/dl; globulin, 2.7 g/dl; alkaline phosphatase, 110
U/liter (normal, 1—125 U/liter); and cholesterol, 260 mg/dl. The plasma
intact PTH was 110 pg/mI (normal, 20—55 pg/ml). The hematocnt was
30%. A peritoneal equilibration test (PET) 4 months prior to the
peritonitis, performed 4 hours after the infusion of peritoneal dialysis
solution containing 2.5 g/dl glucose, showed a drain volume of 2550 ml;
the ratio of the dialysate glucose concentration at 4 hours dwell time to
the dialysate glucose concentration at zero dwell time (D/DO) was 0.48
[1].
In the months following his hospitalization for peritonitis, symptoms
of fluid retention appeared; systemic hypertension developed, and the
plasma urea and creatinine levels rose. A repeat PET showed a severe
ultrafiltration defect (a drain volume of 2080 ml) and a DIDO glucose
ratio of 0.42 [1]. Other laboratory findings included a BUN of 108 mg/dl;
creatinine, 14.6 mg/dl; calcium, 10.2 mg/dl; phosphorus, 6.8 mg/dl;
albumin, 3.2 g/dl; globulin, 2.7 g/dl; and hematocrit, 30%. The CAPD
was stopped and hemodialysis treatment was initiated. When the
Tenckhoff catheter was removed, the surgeons found a marked thick-
ening of the parietal peritoneum.
Discussion
DR. CIDL0 CHAIM0vITz (Head, Department of Nephrology,
Soroka Medical Center of Kupat Holim, and Professor of
Medicine, The Ben Gurion University of the Negev Center for
Health Sciences, Beer-Sheva, Israel): This patient had been
successfully treated with CAPD for about 3 years. His perito-
neal creatinine clearance was normal, and accordingly his fluid
balance and nutritional status were excellent. Thirty-three
months after commencement of CAPD, he had severe perito-
nitis due to Staphylococcus aureus. In the following months,
signs of under-dialysis and peritoneal ultrafiltration failure
required his transfer to hemodialysis. Clinical data, radiographs
of the peritoneal cavity, and the surgeon's description of the
pentoneum led to a diagnosis of peritoneal fibrosis.
Although rare, a decrease in ultrafiltration is a worrying
condition in patients on CAPD [2—151. In most cases the
decrease is due to an increased permeability of the peritoneum
to glucose, which is rapidly absorbed from the dialysate.
Consequently the dialysate/serum osmotic gradient dissipates
quickly and retards the ultrafiltration [1, 3, 16]. Patients with
this condition, known as type-I ultrafiltration (UF) failure, have
difficulty in removing fluid during dialysis, although the urea
and creatinine clearances are maintained or even increased.
This impairment in ultrafiltration occurs more frequently in
patients on long-term peritoneal dialysis, although it can be a
temporary condition lasting only a few weeks after acute
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peritonitis. In a number of patients with type-I UF failure who
underwent peritoneal biopsies, the mesothelial cell layer was
severely damaged [7, 17]. The condition can be treated by using
hypertonic dialysis solution more frequently and/or by shorten-
ing the length of dwell time. Less often, the impaired ultrafil-
tration is due to a reduction in the surface area of the peritoneal
membrane (type-I! ultrafiltration failure) and is associated with
a normal or low peritoneal permeability to glucose [3, 6, 7, 16].
Type-Il UF failure occurs most frequently in patients recover-
ing from severe and prolonged peritonitis, in which the patho-
gen is usually Staphylococcus aureus or fungus. Peritoneal
biopsies show that the delicate pentoneal structure is replaced
by extensive scar tissue, and laparotomies have revealed mul-
tiple pentoneal adhesions [3, 15]. In the patient under discus-
sion, the peritoneal damage can be classified as type-Il ultrafil-
tration failure. As happened in the patient described here, most
patients in this category must change their treatment from
CAPD to hemodialysis.
In this Forum, I plan to review a variety of documented
investigations published to date that address some of the major
problems arising in CAPD treatment.
Pathogenesis of peritoneal fibrosis
Pentoneal biopsies from uninfected CAPD patients reveal
significant alterations in the structure of the peritoneal mem-
brane [18—20]. Large numbers of mesotheial cells were seen in
the process of detaching from the peritoneal surface and being
replaced by a lively upward migration of precursor cells.
Damage to the mesothelial cells, evidenced by the almost
complete disappearance of the microvilli, also has been seen in
biopsy specimens from CAPD patients.
The histologic changes might result from exposure to the
peritoneal dialysis solution, which is highly unphysiologic [19,
20]. The low biocompatibility of the available dialysis solution
is due to its very low pH, high osmolality, and high glucose and
lactate content. This hypothesis is supported by recent studies
in vitro demonstrating that severe damage is caused by expo-
sure of primary cultures of human omentum-derived mesothe-
lial cells to the commercially available peritoneal dialysis solu-
tion (CDS) [21, 22].
Dobbie recently discussed the pathogenesis of peritoneal
fibrosis in CAPD patients [23]. He presented evidence strongly
supporting the concept that severe injury to the peritoneal
mesothelial cells is the initiating event that ultimately leads to
fibrosis of the peritoneum. If, in addition to the chronic irritant
effect of the dialysis solution, a severe or prolonged peritonitis
occurs, the mesotheial cell injury may be so extensive that the
healing process cannot keep pace, thus leaving large areas of
submesothelial tissue denuded of mesothelial cells and covered
by a thick mantle of fibnn in their place. This fibrin layer, if not
degraded, will progressively organize into fibrous tissue.
The submesothelial tissue also can be damaged by direct
contact with the extremely high concentrations of glucose in the
dialysis solution through a process of nonenzymatic glycation
of the proteins [23]. Glycated collagen fibers are less soluble
and more resistant to degradation than is normal collagen; this
difference can lead to the accumulation of extracellular matrix
in the submesothelial layer.
Fibrogenic cytokines and ultrafiltration failure
Growth factors in the dialysate have been speculated as a
pathogenic mechanism in peritoneal fibrosis and consequent
ultrafiltration failure [3, 24, 25]. So-called fibrogenic cytokines,
such as platelet-derived growth factor (PDGF), transforming
growth factor beta (TGF/3), interleukin-1 (IL-i), and tumor
necrosis factor alpha (TNFa), can be produced by activated
mononuclear phagocytic cells. Both PDGF and TGF/3 directly
stimulate fibroblast proliferation, whereas IL-i acts indirectly by
inducing fibroblasts to secrete PDGF [26—28]. Transforming
growth factor f3 stimulates the synthesis of matrix compounds,
including fibronectin, collagen, and proteoglycan [29]. Shimokado
et al demonstrated that activated peritoneal macrophages of
patients treated with CAPD can secrete a growth factor that
stimulates proliferation of fibroblasts [30]; a significant portion of
this mitogenic activity was accounted for by a molecule similar to
PDGF. This issue was further investigated by Breborowicz and
colleagues, who demonstrated that culture medium, conditioned
by peritoneal leukocytes, stimulates proliferation of fibroblasts
[25].
Selgas and coworkers recently described mitogens found in
the dialysate of CAPD patients that stimulated proliferation of
mouse and human fibroblast [31]. Interestingly enough, mito-
genic activity of the dialysate was greater in patients with low
ultrafiltration, but the factors responsible for the connective-
tissue cell proliferation were not defined. Lamperi et al reported
data supporting the view that excessive intraperitoneal synthe-
sis of cytokines plays a significant role in the pathogenesis of
peritoneal fibrosis and consequent peritoneal functional failure
[24]. In comparison to patients with normal ultrafiltration or
type-I ultrafiltration failure, they found a higher concentration
of IL-i and interferon-gamma (IFNy) in the dialysate of patients
with type-Il UF failure. In patients with type-Il UF failure,
peritoneal lymphocytes and macrophages stimulated in vitro
released significantly higher quantities of IL-i and IFNy as
compared with cells from patients with type-I UF failure or
normal UF. There is still much to learn regarding the role of
cytokines in peritoneal fibrosis in patients undergoing CAPD.
Moreover, we need to investigate the feasibility of therapeutic
agents which, by inhibiting the synthesis of collagen and the
proliferation of fibroblast, might improve this condition.
Histologic evidence of fibrous tissue accumulation in the
submesothelial layer is not always associated with clinical
evidence of peritoneal membrane dysfunction. Peritoneal fibro-
sis documented by biopsies of patients undergoing CAPD has
been reported to occur even though the ultrafiltration function
and peritoneal clearance were normal. It is generally believed
that a very small fraction of the total peritoneal surface is
actually involved in the dialytic procedure [18]. Only that area
in strict juxtaposition with the peritoneal capifiaries is directly
involved in the peritoneal fluxes of the fluids and solutes [18].
One can therefore reasonably assume that a wide deposition of
fibrotic tissue in the membrane will be required to cause
dysfunction of the peritoneal membrane.
Macrophages and peritoneal host defense
In spite of great improvements in CAPD techniques, partic-
ularly in the connecting systems, peritonitis remains the most
common cause for patients leaving a CAPD program [32—35].
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Growing evidence suggests that CDS has a detrimental effect on
the host defense mechanism of the peritoneal cavity [36—381. I
would like to review the elements involved in the host defense
against micro-organisms invading the peritoneal cavity and how
CDS suppresses their function.
Macrophages are the predominant cells in the dialysate of
uninfected patients undergoing acute or chronic peritoneal
dialysis. The dialysate-elicited macrophages have functional,
immunophenotypic, and cytochemical features that differ
uniquely from normal peritoneal macrophages [39—42]. Some
investigators maintain that the pentoneal macrophages of
CAPD patients are immature cells, reflecting the influx of
younger monocytes due to the rapid turnover of the pentoneal
cells. Goldstein et al found that peritoneal macrophages of
CAPD patients exhibited a low uptake of eicosanoid precursors
and lack the membrane-bound enzyme ecto-5' nucleotidase that
normally accumulates in mature macrophages [39]. Using these
observations, the authors suggested that the peritoneal macro-
phages of CAPD patients constitute an immature monocyte-like
population caused by the daily shedding of 30 million to 40
million of these cells into the dialysate. However, subsequent
characterization of functional markers of dialysate-elicited pen-
toneal macrophages and research into the pattern of endoge-
nous peroxidase activity of these cells supported the notion that
they are phagocytes stimulated by a state of chronic inflamma-
tion in the peritoneal cavity. For instance, Lewis and Holmes
found that peritoneal macrophages from patients treated with
CAPD, contrary to macrophages in their peripheral blood,
displayed increased binding of the chemotactic peptide C5a,
increased expression of Fc receptors, and increased expression
of HLA DR and CD14 antigens [42]. Cytochemical studies
carried out in rats by Bos et al demonstrated that an intraperi-
toneal injection of commercial dialysis solution changes the
pattern of peroxidase activity of the peritoneal cells: 24 hours
after dialysis fluid infusion, the number of exudate macrophages
displaying peroxidase activity in the lysosomal granules rose
sharply [43]. This cytochemical pattern was similar to that
described in the dialysate-elicited peritoneal macrophages of
uninfected patients [44]. The authors suggested that the com-
mercial dialysis solution used in CAPD induces a state of
chronic sterile inflammation in the pentoneal cavity, thereby
activating the macrophages [43, 45].
The functional capacity of the macrophages harvested after
an intraperitoneal infusion of CDS also has been the object of
extensive research. However, controversy continues among
scientists as to the results. Peterson et al [37] and Davies and
colleagues [40] demonstrated that the ability to mount a phago-
cytic respiratory burst by stimulated peritoneal macrophages
was greater for patients treated with CAPD than for normal
controls. Moreover, the candidicidal activity of the dialysate-
elicited macrophages was tenfold higher than that occurring in
normal peritoneal macrophages. On the other hand, some
investigations have described a normal or slightly decreased
bactericidal capacity of the dialysate-elicited macrophages rel-
ative to peritoneal macrophages from healthy controls [39, 46].
The reason for the considerable controversy regarding the
functional characteristics of the peritoneal macrophages in
patients treated with CAPD is not clear. Detailed clinical
studies will be necessary to establish the relationship between
peritoneal macrophage function and such clinical features as
nutrition, adequacy of dialysis treatment, and the sufficiency of
calcitriol replacement. Bearing these reservations in mind, I
believe that the weight of evidence supports the contention that
dialysate-elicited peritoneal macrophages are normal or stimu-
lated cells.
The peritoneal macrophages in patients treated with CAPD
are viewed as the peritoneal cavity's first line of defense against
invasion of microorganisms. However, after the infusion of 2 to
3 liters of dialysis solution, the number of macrophages in the
peritoneal cavity drops to values as low as 103—104/ml of
effluent. This dilution makes the probability of macrophage-
microorganism interaction very low in the early stages of
peritonitis [47]. Thus it would appear that the efficacy of the
macrophages, which greatly exceeds innate functions such as
phagocytosis and killing of invading bacteria, is mostly accom-
plished by the production of potent inflammatory cytokines
such as IL-i and TNFa. These cytokines can interact and
stimulate other pentoneal resident cells and thus amplify in-
flammatory signals originating in the macrophages. To illustrate
such a mechanism, I would like to demonstrate how the
mesothelial cells, which constitute the majority of normal
peritoneal resident cells, are able to amplify inflammatory
messages from the macrophages in the early stages of peritoni-
tis. This interactive process emphasizes their contributory role
in the inflammatory reaction of the peritoneum following micro-
bial invasion.
Cytokine synthesis by peritoneal mesothelial cells
I infer from recent intensive investigations that the peritoneal
mesothelial cells have ceased to be considered as a passive
lining membrane and have come to be viewed as the target for
macrophage-related cytokines [48]. Because the mesothelial
cells are strategically placed in close juxtaposition both to
peritoneal macrophages and underlying mesothelial microvas-
cular endothelium, these cells are well situated to regulate the
bi-directional interaction between the macrophages and the
vascular cells.
At our laboratory in Beer-Sheva, my colleagues and I re-
cently investigated the ability of human pentoneal mesothelial
cells in culture to produce interleukin-l when stimulated either
by E. coli lipopolysaccharide (LPS), TNFa, or IL-la singly, or
by LPS combined with any one of these cytokines [49]. Lipo-
polysaccharide is the main inflammatory product of gram-
negative bacteria; TNFa and IL-i are released into the perito-
neal fluid when macrophages come in contact with bacteria. We
tried to simulate the inflammatory events occurring during
bacterial peritonitis. Stimulation by LPS elicited a small but
significant release of the two forms of IL-i: IL-i a and IL- ip,
but no significant stimulatory effect was seen when mesothelial
cells were incubated with either TNFa or IL-ia alone. How-
ever, the combination of LPS with either IL-la or TNFa
synergistically increased IL-i release by the mesothelial cells.
The presence of mRNA of IL-la and IL-1f3 was determined by
polymerase chain reaction (PCR) amplification of reverse tran-
scribed RNA. We detected expression of IL-ia and IL-ip
mRNA when the mesothelial cells were stimulated with either
LPS, TNFa, or IL-ia , but the combination of LPS with either
one of the cytokines had no synergistic effect. We concluded
that the synergistic effect of combinations of LPS with TNFa or
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IL-la on the release of IL-i probably occurs at the post-
transcriptional level.
The expression of the IL-i gene and the translation of IL-l
mRNA are distinct and dissociated processes [50, 51]. For
example, certain stimuli such as Cia or cell adherence to a glass
surface trigger IL-i gene expression without translation into
protein. The cells containing untranslated IL-i mRNA are
"primed," and even sub-stimulatory levels of other activators,
such as LPS or IL-i itself, induce a translational signal. How
"priming" in the mesothelial cells constitutes one of the mech-
anisms whereby LPS and TNFa are made highly synergistic in
the release of IL-l requires further investigation.
I believe the results of our work highlight the important role
of the mesothelial cells in the host defense mechanism of the
peritoneal cavity. First, we have demonstrated that stimulated
human peritoneal mesothelial cells produce a potent pleiotropic
cytokine, like IL-l, capable via other IL-l-inducible cytokines
of amplifying macrophage inflammatory signals. Second, IL-i is
an important modulator of the vascular endothelial cell function
and thus might interact in a paracrine fashion with the neigh-
boring peritoneal capillary network. As a consequence, the
endothelial cells will be stimulated into participating in the
inflammatory process by synthesizing vasodilatory molecules,
neutrophil chemotactic peptides, and by expressing adhesion
molecules; as a result, more inflammatory cells will be recruited
[52—56].
Expression of molecules that mediate leukocyte-endothelial
cell adhesion is an early prerequisite in the inflammatory
response [54, 55, 57]. These molecules facilitate both adhesion
to endothelial surface and transendothelial migration of leuko-
cytes at the site of the inflammation. After crossing the perito-
neal capillary wall, the migrating leukocytes also must traverse
the mesothelial cell layers to reach the inflamed site in the
peritoneal cavity. Evidence reveals that adhesion molecules
also are expressed on the surface of the mesothelial cells. Jonjic
and colleagues recently found the expression of intercellular
adhesion molecule-l, ICAM-l, and the vascular cell adhesion
molecule YCAM- 1 in ascites-derived mesothelial cells [58]. The
expression of these adhesion molecules could be up-regulated
by exposure of the mesothelial cells to TNFa and IFN7. Their
data also revealed that activation of monocytes with LPS and
IFNy considerably enhanced their adherence to the mesothelial
cells, a process that can be blocked by anti-CD18, the leukocyte
ligand of ICAM-l. In a preliminary communication, Zeille-
maker et al described the presence of ICAM-l and VCAM-l,
but not endothelial leukocyte adhesion molecule-l (ELAM-l),
in monolayers of human peritoneal mesothelial cells [59]. They
also found that stimulation of the polymorphonuclear leuko-
cytes by the chemoattractant C5a was necessary for significant
binding of the leukocytes to the mesothelial cells. In our
laboratory we also demonstrated the expression of ICAM-l in
human mesothelial cells and a strong binding of LPS-stimulated
leukocytes to the mesothelial monolayer (Fig. 1).
Further investigations have been undertaken recently explor-
ing a role for the mesothelial cells in regulating inflammatory
responses within the peritoneal cavity. Like the pleural me-
sothelium, the peritoneal mesothelial cells respond to stimula-
tion by IL-i and IFN7 by synthesizing the highly potent
neutrophil chemotactic factor interleukin-8 (IL-8) [58]. Produc-
tion of IL-8 by omentum-derived mesothelial cells also was
recently reported by Topley et al [60]. In addition to being a
potent leukocyte chemoattractant, IL-8 stimulates the release
of superoxide and degranulation by leukocytes as well as
leukotriene synthesis [61]. Although peritoneal macrophages
appear to be the predominant source of IL-8, the close prox-
imity of the mesothelial cells to the peritoneal capillaries makes
them uniquely situated to regulate the recruitment of neutro-
phils in the peritoneal cavity, at least in the early stages of the
infection.
Human peritoneal mesothelial cells also can be induced to
synthesize interleukin-6 (IL-6), a polypeptide with a complex
spectrum of biologic effects [58, 62]. Interleukin-6 activity
A
B
Fig. 1. Adherence of unstimulated (A) or LPS-stimulated (B) polymor-
phonuclear leukocytes to omentum-derived human mesothelial cell
monolayer. Polymorphonuclear leukocytes were stimulated for 30 mm
with 1 zg/ml of LPS and then incubated for 60 mm with the mesotheial
cells. The nonadherent cells were removed by three washes with
medium.
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includes regulation of B cell immunoglobulin production and
stimulation of hepatic acute-phase protein synthesis during
inflammation [63].
Dialysis solution and phagocytic cell function
In 1981, Duwe, Vas, and Weatherhead first showed that
incubation of human peripheral blood leukocytes in peritoneal
dialysis solution inhibited the production of reactive oxygen
species, phagocytosis, and bacterial killing [64]. Further inves-
tigation by Alobaidi et al in the mid-1980s showed that phago-
cytic function of peritoneal macrophages was significantly
suppressed by a pre-incubation period of only 10 minutes in
CDS. Incubation in CDS for 30 minutes completely abolished
phagocytosis even though the cells remained viable [65]. In this
study, the macrophages were pre-incubated in the dialysis
solution for various periods of time and then replaced in a
normal cell culture medium for one hour before phagocytic
function was assessed. This experimental design also provided
evidence that the suppressor effect of short exposure to CDS
was not reversible even one hour alter the macrophages were
returned to a "normal" environment. If these findings can be
extrapolated to CAPD, the initial suppressor effect of the CDS
might continue despite the gradual normalization of the dialy-
sate (pH and osmolality) during its dwell time in the peritoneal
cavity. Other investigators have corroborated these findings
and have presented evidence that incubation in unused dialysis
fluid inhibits the generation of oxygen-free radicals by activated
peripheral blood leukocytes as well as by peritoneal macro-
phages [66—68]. By the late 1980s, these studies had demon-
strated a suppressor effect of unused dialysis solution on the
various functions of the phagocytic cells. However, the identity
of the chemical components responsible for the cytotoxicity
was still not firmly defined. Topley and co-authors studied this
issue in depth [69]. They incubated human peritoneal polymor-
phonuclear leukocytes and peritoneal macrophages in an un-
used pentoneal dialysis solution that contained 35 mM of
lactate and had a pH of 5.3 and an osmolality of 347 mOsm/kg
H2O (made hypertonic by the addition of 1.5% glucose). In a
parallel set of experiments, similar cells were incubated in a
phosphate-buffered saline solution (PBS). After an incubation
period of 30 minutes, the chemiluminescence response to
opsonized zymosan was determined. Values for chemilumines-
cence response also were obtained with cells pre-incubated in
PBS and supplemented either with 35 mM lactic acid or with
glucose to yield an osmolality of 400 mOsm/kg; the pH of the
solutions was adjusted either to 5.3 or 7.3. Pre-incubation in the
unused dialysis solution or in the acidic PBS supplemented with
lactic acid had a strong and almost identical suppressive effect
on the chemiluminescence response. But the glucose-supple-
mented PBS did not interfere with the subsequent chemilumi-
nescence response to opsonized zymosan. The authors con-
cluded that none of the components of CDS individually, such
as high glucose, high lactate, or low pH (5.3), had any inhibitory
effects on the production of oxygen radicals by phagocytic
cells. The chemiluminescence response was strongly sup-
pressed, however, when lactate and a low pH were concomi-
tantly present in the incubation solution.
The influence of hyperosmolality and the high glucose con-
tent of the dialysis solution on phagocytic cell function were
also investigated by Van Bronswijk and colleagues [66]. They
examined the ability of polymorphonuclear leukocytes, mono-
cytes, and peritoneal macrophages to mount a respiratory burst
and phagocytosis of bacteria when exposed to media containing
glucose concentrations ranging from 0.5% to 8.0%. They found
a significant inhibition of chemiluminescence only when the
cells were exposed to a glucose concentration higher than 4.0%,
and a detrimental effect on phagocytosis at glucose levels higher
than 8.0%. These data differ from those of Liberek and cowork-
ers, who found a suppressor effect on polymorphonuclear cell
phagocytosis when glucose was added to the incubation me-
dium in concentrations of 2.7% and higher [70]. The reason for
the discrepancy in the results is not clear.
The mechanism by which the hyperosmolar solutions impair
phagocytic cell function deserves further investigation. We
studied volume-regulating behavior of peritoneal macrophages
suspended in CDS. We found a rapid decrease in volume as
expected from hyperosmotic stress, and this initial shrinkage
phase was followed by yet another swelling towards normal size
(unpublished observation). The data demonstrate that the peri-
toneal macrophages can regulate their volume when exposed to
hypertonic dialysis fluid. Further investigations are needed to
define the mechanisms by which dialysis solutions containing
high glucose concentrations have a detrimental effect on the
function of phagocytic cells.
Peritoneal dialysis fluid and cytokine release
We recently examined the effect of peritoneal dialysis solu-
tion on the production of IL-i and TNFa by peritoneal macro-
phages [71]. The cells were pre-incubated for various periods of
time in unused CDS (1.5% glucose), then returned to the cell
culture medium, and subsequently stimulated with LPS. After a
short pre-incubation period of 15 minutes in the dialysis solu-
tion, the cells had a 50% decrease in the release of TNFa; alter
one hour, the activity of TNFa was undetectable. We observed
this suppressor effect of CDS on TNFa activity in the superna-
tant and cell lysates. We suggested that the inhibitory effect of
CDS on TNF occurs at the production level and not at the
secretion level. To define the mechanism by which CDS mark-
edly attenuates LPS-induced TNFa production by the macro-
phages, we studied the effect of the dialysis solution on induc-
tion of TNFa message. We measured LPS-induced TNFa
mRNA production in human peritoneal macrophages by PCR
and in a macrophage-like cell line, P388D1, by Northern blot-
ting. We found that treatment of the cells with CDS for only 5
to 15 minutes was sufficient to cause a marked decrease in the
level of TNFa mRNA in both the macrophages and the cell line.
In additional experiments, we investigated the physicochemical
constituents of the dialysis solution that are responsible for the
inhibitory effect of CDS on TNFa production. Cells were
pre-incubated for 45 minutes in the test solutions and then
stimulated with LPS. Total RNA was extracted, size fraction-
ated by 1.4% formaldehyde agarose, blotted, and hybridized
with 32P-labeled TNFa and J3 actin probes. Cells were pre-
incubated in test solutions as follows (Fig. 2): CDS (lane 1),
lactate-free CDS (lane 2), glucose-free CDS (lane 3), lactate-
and glucose-free CDS (lane 4), glucose-free CDS with added
0.2% mannitol (lane 5), RPM! medium (lane 6). We noted that
pre-incubation of LPS-stimulated macrophages in a medium to
which 1.5 g/dl glucose was added, and with a pH adjusted to
5.2, did not affect either the TNF activity in the supernatants or
a S °!fl
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Fig. 2. Effect of CDS constituents on the
expression of TNFa mRNA in the
macrophage-like cell line P388D1 by Northern
blot technique.
the level of the TNFa mRNA signal. By contrast, pre-incuba-
tion of the cells in a medium acidified to a pH of 5.2 in the
presence of 35 mM of lactate caused a marked attenuation of
the TNFa mRNA signal. These results conform with those of
Topley et al, who also found that a low pH and a high lactate
concentration play an important role in mediating the suppres-
sor effect of CDS in macrophage-phagocytosis [69].
The fundamental mechanism of the suppressor effect of CDS
on TNF production was further investigated in our laboratory
when we looked at some aspects of signal transduction in
pentoneal macrophages. A DNA binding protein, NF-KB, me-
diates, in a broad array of cells, signal transduction between
cytoplasm and the nucleus [72, 73]. In most cells, the pre-
formed NF-KB transcription factor is complexed with a cyto-
plasmic inhibitor named 1KB. Induction of NF-,cB by cellular
activation involves the disassembly of the NF-KB/IKB complex,
perhaps by phosphorylation of 1KB, allowing the migration of
the transcription factor to the nucleus. The interaction of
NF-KB with the TNFa promoter might be required for efficient
LPS-mediated transcriptional activation of the TNFa gene [74,
75]. The suppressor effect of dexamethasone on TNFa tran-
scription is associated with decreased NF-KB activity. These
data led us to investigate the pattern of NF-KB activity in
nuclear extracts prepared from macrophages. We used a gel
retardation assay (Fig. 3). Nuclear extracts were isolated from:
A Non-stimulated and LPS-stimulated P388D1 macrophage-like
cell line, with or without pre-incubation in CDS for 15 or 30
mm; B Non-stimulated and TPA+Ionomycin-activated EL4
cells that were positive controls for the normal migration
pattern of NF-KB; and C Competition experiment using 100-fold
molar excess of unlabeled NF-KB binding oligonucleotide. Gel
retardation assays were performed with a 32P-radiolabeled
NF-KB binding oligonucleotide. Protein-oligonucleotide com-
plexes were identified by autoradiography after electrophoretic
separation in 5% TBE acrylamide gels. As Figure 3 shows,
NF-KB was detectable in the nucleus of the LPS-stimulated
macrophages. After a short, 15-minute treatment of the cells
with CDS, however, activation of NP-KB by LPS was markedly
suppressed. Other nuclear factors such as AP-1 were not
affected by exposure of the cells to CDS. Thus it seems
reasonable to assume that the inhibitory effect of CDS on TNFa
release by activated pentoneal macrophages can be explained
at least partially by an effect of this cytokine at a transcriptional
level.
Jones et al recently studied the effect of CDS on the capacity
A B C
Fig. 3. Effect of CDS on NF-,.B DNA binding by gel retardation
assays. The arrows indicate the retarded bands of (a) non-specific
binding activity, (b) the active NF-KB p65-p5° heterodimer, and (c) the
inactive p5° homodimer.
of mononuclear and polymorphonuclear leukocytes to release
TNFa [76]. Like us, they detected a strong suppressor effect of
the dialysis fluid on TNFa release. Their experiments on the
physicochemical components responsible for the depressive
effect of the dialysis solution revealed that the low pH and
lactate exhibited a strongly depressive effect on TNFa. Unlike
our results, however, a mild but significant suppressor effect
was seen when they added only glucose to the incubation
solution at concentrations as low as 1.5%. This contradiction of
the effect of glucose on TNFa release could be due to the
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different assay systems used and to the fact that, in Jorres'
experiments, cells were incubated in the glucose-containing
solution for 2 hours, a much longer period than we used. In that
report and subsequent others, these investigators also noted a
suppressor effect of CDS on the release of leukotriene B4, a
powerful chemoattractant metabolite of arachidonic acid [76,
77].
We then investigated the effect of CDS on the release of IL-i
by LPS-stimulated macrophages and found that this cytokine is
also suppressed by the dialysis fluid. Unlike TNFa, however,
after only one hour of exposure to CDS, IL-i release declined
significantly in the culture medium. Furthermore, 1.5% glucose
was required in the incubation medium in addition to lactate and
a low pH to obtain an inhibitory effect on IL-i release compa-
rable to that in the experiments carried out with CDS. We did
note with interest that IL-i and TNFa, which share so many
similar biologic functions, displayed such different levels of
sensitivity to the inhibitory effects of CDS. The reason for this
difference is not clear and warrants further study.
Collectively, these observations support the view that the
combination of low pH and high lactate in the peritoneal
dialysis fluid is detrimental to the function of the peritoneal
macrophages. As far as the roles of hypertonicity and high
glucose concentration are concerned, it would seem that in
incubation media containing 1.5 g/dl glucose, as in standard
dialysis solution, macrophage function is not compromised, but
higher concentrations of glucose might be detrimental. The
available evidence, however, does not provide us with enough
information regarding the specific cellular mechanism(s) in-
volved in the suppressor effect of the lactic acid and low pH of
the dialysis solution on the function of phagocytes.
Cellular pH and toxicity of dialysis solutions
Many disparate biologic functions depend on the mainte-
nance of a normal cytoplasmic pH [78]. In patients treated with
CAPD, the fine regulation of cytoplasmic pH of the pentoneal
cells can be disrupted due to their repeated exposure to the very
low pH of the commercial dialysis fluid. A profound defect was
observed in the ability of phagocytosis to mount a respiratory
burst and to produce cytokines when peritoneal macrophages
were exposed to CDS at its marketed pH of 5.2; these func-
tional defects were corrected by the adjustment of the dialysis
fluid pH to 7.4 [69, 79, 80].
We hypothesized that CDS suppresses macrophage function
by causing a drop in the cytoplasmic pH. To verify this
assumption, we measured the cytoplasmic pH of peritoneal
macrophages fluorometrically while they were exposed to ei-
ther CDS or to a physiologic saline solution adjusted to a pH of
5.2 [81]. We found that exposure of the macrophages to CDS
was associated with a rapid and profound reduction in intracel-
lular pH of the macrophages; the level achieved was 0.5 units
lower than the cytoplasmic acidification induced by the physi-
ologic saline solution (Fig. 4A).
After instillation of the dialysis solution into the peritoneal
cavity, the dialysate rapidly becomes much less acidic; it
reaches a pH of 6.5 after 15 minutes and a pH of 7.0 after
approximately 30 minutes of dwell time [82]. This increase in
dialysate pH is due both to the diffusion of bicarbonate from the
blood into the peritoneal cavity and also to the mixing of the
fresh dialysis solution with residual fluid in the peritoneal cavity
at the end of a dialysis cycle. To simulate the compositional
changes in the first 30 minutes of dwell time, we conducted
experiments exposing the macrophages to CDS in which the pH
was adjusted to 7.0 by the addition of NaOH. Again we found
that at any pH in the incubation medium, the cytoplasmic pH
was always much lower in the cells exposed to CDS than in the
cells exposed to the saline solution (Fig. 4B).
In commercial peritoneal dialysis solutions, lactate is the
organic ion used as a base substitute, a proportion of which is
undissociated in the acid pH of CDS. Consequently, we as-
sumed that the lactate in its undissociated state (that is, lactic
acid) traverses the plasma membrane into the macrophages and
causes intracellular acidification. To confirm this hypothesis,
we exposed the macrophages either to a lactate-containing
saline solution or to CDS of similar pH. In both cases, the
reduction in the cytoplasmic pH was identical (Fig. 4C). Thus it
would seem that the diffusion of lactic acid constitutes the main
acid generation pathway of the macrophages when they are
exposed to CDS.
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Fig. 4. io BCECF-loadedperitoneal macrophages were incubated at 37°C, and the time course of cytosolic pH (pHi) was recorded. The baseline
pHi was determined in Hepes buffered saline solution (HBSS) at pH 7.4. The traces of pHi after exposure to either CDS or HBSS at pH 5.2 is
shown in A and at pH 7.0 is shown in B. The traces after the addition of 40 mM of lactate to HBSS is shown in C. Traces represent one of five
similar experiments.
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During incubation of macrophages in CDS, the initial reduc-
tion of cytoplasmic pH always was followed by a gradual
recovery of the pH toward baseline (Fig. 4B). Approximately
40% of pH recovery could be inhibited by amiloride, an
inhibitor of the Na/H exchanger. The remaining cytoplasmic
pH recovery was insensitive to amioride and was independent
of sodium, but it could be inhibited by treatment of the cells
with dicyclohexylcarbodiimide, an H-ATPase blocker. These
data support the idea that the peritoneal macrophages possess
two efficient proton-extruding mechanisms involved in the
cytoplasmic pH recovery of macrophages acidified with the
dialysis solution: a sodium/proton exchanger and a proton
pump.
In certain cells such as hepatocytes, lymphocytes, and me-
sangial cells, the sodium-dependent C11HC03 exchanger is
important in protecting against cytoplasmic acidification [83,
84]. The sodium dependent C1/HC03 exchanger, which
exchanges extracellular sodium and bicarbonate for intracellu-
lar chloride, can be blocked by the stilbene derivative, 4-4'-
diisothyocyanostilbene-2-2' disulfonic acid (DIDS). Bicarbonate
accumulates in the dialysate during dwell time in the peritoneal
cavity, and if this exchanger is present in the peritoneal macro-
phages, it possibly could protect against the acidifying effect of
CDS.
To evaluate this assumption, we determined the cytoplasmic
pH of the macrophages exposed to CDS buffered to a pH of 7.0
with C02-HC03. The decrease in the cytoplasmic pH was
similar to that in cells exposed to a bicarbonate-free CDS
buffered to a pH of 7.0. Moreover, the reduction in cytoplasmic
pH was not affected when we added DIDS to the incubation
media. As far as we can extrapolate these in-vitro findings to the
in-vivo conditions inside the peritoneal cavity, we can conclude
that the sodium-dependent C1/HC03 exchanger is not impor-
tant in protecting macrophages against the acidifying effect of
commercially available dialysate solution.
The finding that CDS produces acidification of the macro-
phages led us to question whether the cytoplasmic acidification
and the impaired immune function of these cells are causally
related. Although no unequivocal evidence exists regarding this
relationship, some data suggest that a decrease in cytoplasmic
pH indeed does impair the immune function of phagocytic cells.
Let me illustrate such a phenomenon.
It is well known that the activity of cellular enzymes depends
on an optimal pH. The NADPH oxidase is an enzyme that
catalyzes the reaction of 02 with NADPH to form NADP and
superoxide; the optimal pH range for this enzyme activation is
6.8 to 7.9 [85]. We can logically assume, therefore, that when
the macrophage-cytoplasmic pH falls well below 6.5, exposure
to CDS will limit the activation of the NADPH oxidase and
thereby impair the generation of superoxide. In an elegant
publication, Rotstein and coworkers described the effect of a
reduced cytoplasmic pH on superoxide production by phago-
cytes [85]. These researchers tried to determine why certain
anaerobic bacteria, particularly Bacteroides species, increased
their virulence by secreting large amounts of short-chain fatty
acids such as succinic acid into the acidic milieu of the
inflammatory sites. The augmented virulence of these bacteria
is accounted for by their suppressor effect on leukocyte func-
tion. Rotstein and colleagues measured the cytoplasmic pH of
neutrophils after exposing them to a medium simulating the
micro-environmental conditions created by the anaerobic bac-
teria: a high concentration of succinic acid and a pH adjusted to
6.5 or less. The cytoplasmic pH of these cells was profoundly
reduced and was associated with an impaired capacity of the
cells to generate superoxide. To establish that the impairment in
neutrophil oxidative metabolism was caused by the reduction in
the cytoplasmic pH, these workers clamped the cytoplasmic pH
of these cells at various levels and observed that clamping
cytoplasmic pH to values below 6.0 was associated with a
defective generation of superoxide anions. On the basis of these
results, the authors concluded that neutrophil function was
compromised by the entry of succinic acid into the cells and
release of protons from succinic acid, thereby acidifying the
cytoplasmic compartment.
Interestingly enough, this scenario resembles the conditions
prevailing in the peritoneal cavity of patients treated with
CAPD after instillation of CDS, in which lactic acid accumu-
lates in the peritoneal macrophages and results in a profound
reduction in macrophage cytoplasmic pH. It is tempting for us
to speculate whether the inhibitory effect of CDS superoxide
production of peritoneal macrophages is caused by its acidify-
ing effect and a decreased activity of NADPH oxidase.
Vitamin D metabolism and peritoneal host defense
Thus far, I have concentrated on the role of cytokines and
intracellular pH of macrophages in peritoneal host defense. In
the last decade, we have learned a great deal about the
non-endocrine effects of vitamin D, and I would like to close
this Forum by spending some time discussing the possible role
of vitamin D in peritoneal host defense. Under normal physio-
logic conditions, the kidney is a major source of 1 ,25(OH)2D3,
the most biologically active hormonal form of vitamin D. In the
proximal tubule cells, the enzymatic conversion of 25-OH-D3 to
1 ,25(0H)D3 is catalyzed by the enzyme 25,1 a hydroxylase, a
mitochondrial cytochrome P450-linked mixed oxidase [86, 87].
This reaction is tightly regulated by the serum concentration of
PTH, phosphorus, and 1 ,25(OH)2D3. Like other steroid hor-
mones, the effects of l,25(OH)2D3 are mediated by a nuclear
receptor molecule to which the hormone binds with high affinity
(Kd = 10— 10 M) and selectivity compared with other vitamin D
metabolites. The receptor-hormone complex interacts with a
DNA sequence enhancing the transcription of 1 ,25(OH)2D3-
responsive genes [881.
As I mentioned earlier, evidence is increasing for a biologic
role of l,25(OH)2D3 beyond its regulatory role in mineral ion
homeostasis [89—91]. This hormone also might be locally pro-
duced at sites of tissue inflammation and thus might play a key
role in modulating the function of immune cells. Clinical evi-
dence supporting the role of 1 ,25(OH)2D3 as a modulator of the
immune response is found in the frequent incidence of infection
in patients with nutritional rickets due to abnormal phagocytic
function [92, 93]. Tissue macrophages and circulating mono-
cytes constitutively express receptors for l,25(OH)2D3, but
resting lymphocytes require activation by mitogenic lectins or
specific antigens. In physiologic concentrations, 1 ,25(OH)2D3
inhibits lymphocyte proliferation and IL-2 production but stim-
ulates monocyte/macrophage function [94]. Stimulatory effects
of 1 ,25(OH)2D3 have been documented in macrophage func-
tions such as: phagocytosis, formation of hydrogen peroxide
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and cytotoxicity, expression of Fc receptors, and expression of
IL-1$ and TNFa genes [90, 91, 95—97].
Prehn et al recently investigated the mechanism of the
stimulatory effect of 1,25(OH)2D3 on the synthesis of TNF in
LPS-stimulated macrophages [97]. The authors demonstrated
that pre-incubation of the myelomonocytic cell line U-937 with
1 ,25(OH)D3 markedly potentiates both TNFa mRNA expres-
sion and protein production. The authors presented persuasive
evidence that 1 ,25(OH)2D3-induced TNFa gene expression
occurs not only by a direct transcriptional effect but also by
increased expression of CD14 mRNA, the high-affinity binding
site for the LPS-LPS binding protein complex. The LPS binding
protein has been isolated from the serum and cloned [98].
Lipopolysaccharide complexed to the LPS binding protein is
much more potent than native LPS, and its target in the
monocytes, the CD14 antigen, is up-regulated by 1 ,25(OH)2D3
[97].
Several studies have shown that 1 ,25(OH)2D3, like INF7, is
an important stimulatory factor in the secretion of hydrogen
peroxide by monocytes/macrophages. Cohen and colleagues
demonstrated that pre-incubation for 3 days with 1 ,25(OH)2D3
caused a threefold increase in the secretion of hydrogen perox-
ide in phorbol-myristate-acetate-stimulated human monocytes
[95]. This stimulatory effect was similar in magnitude to that
occurring when the cells were treated with INF7. No synergis-
tic effect was observed, however, when the cells were simulta-
neously treated with both agents. The monocytes' diminished
capacity to produce H202 when the culture period was pro-
longed beyond 7 days could be offset by exposure of the cells to
1,25(OH)2D3. Levy and Malech recently investigated the mech-
anism by which 1 ,25(OH)2D3 potentiates production of super-
oxide by phagocytic cells [99]. Under the influence of
l,25(OH)2D3, human monocytes augment the expression of a 47
kD protein, an important cytosolic molecule involved in the
activation of NADP oxidase.
It is possible that 1 ,25(OH)2D3 plays a special immunoregu-
latory role in the unique pentoneal micro-environment of
patients undergoing CAPD. Peritoneal macrophages of non-
infected patients undergoing CAPD can metabolize 25-OH-D3
to 1,25(OH)2D3 in vitro [100], and the synthesis of this metab-
olite is increased in patients with peritonitis. Synthesis of
1 ,25(OH)2D3 depends on the presence of 25-la hydroxylase in
the macrophages, as evidenced by the fact that this reaction
could be blocked when ketaconazole was added to the incuba-
tion medium. These in-vitro findings could be of clinical signif-
icance for CAPD patients. A decade ago, we showed that
patients undergoing CAPD lose 25-OH-D3 into the dialysate
[101]. We also detected loss of 1,25(OH)2D3 in patients in whom
oral replacement returned the plasma level of this metabolite to
normal [102]. This loss of vitamin D metabolites is mainly due
to the permeability of the peritoneal membrane to the serum
vitamin-binding protein, a 52 kD a2 globulin, to which the 25-
OH metabolite is tightly bound in the circulation. Conse-
quently, the presence of 25-OH-D3 in the dialysate could be a
constant source of supply of substrate for the intrapentoneal
synthesis of l,25(OH)2D3 by the macrophages. Thus, this
metabolite synthesized in the peritoneal cavity or lost into the
dialysate could act as an autocrine or paracrine factor, enhanc-
ing the immune function of the peritoneal macrophages. We
recently published work supporting this supposition [103].
We found that the production of superoxide by PMA-stimu-
lated peritoneal macrophages treated for a 24-hour period with
l,25(OH)2D3 was markedly enhanced in cells obtained from
CAPD patients with a low incidence of peritonitis. However, in
a group of CAPD patients with a high incidence of peritonitis,
the macrophages displayed a different pattern of behavior: the
stimulatory effect of vitamin D was seen only after 3 days of
incubation. The resistance of the macrophages to 1 ,25(OH)2D3
in this group of patients was associated with a high level of
prostaglandin secretion by these cells and could be overcome
by the addition of indomethacin to the culture medium. Our
finding of elevated prostaglandin secretion by macrophages
from patients undergoing CAPD and having a high incidence of
peritonitis concurs with results obtained in a study by Lamperi
and Carozzi [104]. We currently are studying the effect of
1 ,25(OH)2D3 on the synthesis of cytokines by peritoneal mac-
rophages.
A recent publication, in which the function of peripheral
polymorphonuclear leukocytes and monocytes in patients on
chronic hemodialysis was studied before and after oral replace-
ment of l,25(OH)2D3, further supports our work. Hubel and
colleagues found that replacement of 1 ,25(OH)2D3 normalized
monocyte functions such as superoxide generation and bacte-
ricidal capacity [105]. Polymorphonuclear cells functioned nor-
mally in these patients, and 1 ,25(OH)2D3 treatment conferred
no benefit.
One should keep these findings in mind when deciding
whether to administer 1 ,25(OH)2D3 replacement in patients
undergoing CAPD in whom the frequent incidence of low PTH
and a low bone turnover might contraindicate the administra-
tion of this metabolite [106]. It is our practice to administer
1a25(OH)2D3 in doses varying from 0.5—1.0 j.gIday to our
CAPD patients, most of whom are being treated with dialysis
fluid containing a low concentration of calcium (1.5 or 1.25
mMol). We can thereby maintain a normal ionized calcium
concentration in the serum. All our patients receive calcium
carbonate as a binder of phosphate.
Questions and answers
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Thank you, Dr.
Chaimovitz, for an excellent presentation. Given my interest in
acid-base physiology, I'd like to start the question-and-answer
period by asking you to expand on your comments regarding
the pHi of peritoneal cells. What is your methodology, its
validity, and its reproducibility?
DR. CHALMOVITZ: We measured the cytosolic pH of the
peritoneal macrophages fluorometrically after loading the cells
with the pH-sensitive fluorescent dye BCECF. This is a stan-
dard technique for determining cytosolic pH. The peritoneal
macrophages were obtained from a dialysate of an overnight
exchange in peritonitis-free CAPD patients. More than 90% of
the cells were positive to the macrophage/monocyte marker
CD14 monoclonal antibodies by flow cytometry. Calibration of
these cytosolic pHs was performed after releasing the dye by
lysing the cells with Triton and then recording the fluorescent
signal at known pHs. The data presented in the figures are
representative studies of several experiments revealing almost
identical changes in the cystolic pH.
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Da. HARRJNOTON: Are there structural or functional differ-
ences between the abnormal peritoneal cells of the patients
undergoing CAPD and the mesothelial cells from patients with
either cirrhotic or malignant ascites?
DR. CHAIM0vITz: I am aware of one study of patients not
undergoing CAPD that characterized the function of peritoneal
mesothelial cells. This study, by Jonjic et al, demonstrated that
when activated, ascites-derived mesothelial cells from women
with ovarian carcinoma synthesized cytokines and adhesion
molecules similarly to what has been shown with pentoneal
mesothelial cells of CAPD patients [58]. It would be interesting
to further investigate the characteristics of peritoneal mesothe-
hal cells in ascites of patients with salt-retaining disorders such
as cirrhosis of the liver.
DR. HARRINGTON: What is your prescription for a more
physiologic peritoneal dialysis solution?
DR. CHAIMovIrz: In-vitro as well as in-vivo studies have
demonstrated that the suppressor effect of currently available
commercial dialysis fluid on the various functions of phagocytic
cells could be corrected by raising the pH level of this fluid to a
more physiologic value [69, 711. Thus, functions such as the
ability to generate a respiratory burst response, phagocytosis,
killing of bacteria, and release of cytokines were corrected by
raising the pH of the dialysis solution to 7.4.A low pH per se,
however, does not seem to have a detrimental effect on the
function of phagocytic cells. Lactate must be added to the
solution for the inhibitory effect of the incubation fluid to
appear. Consequently, it is vital that more emphasis be put on
research to produce a dialysis solution with a higher pH level.
In my opinion, there is no decisive evidence proving that lactate
in a solution of pH 7.4 is detrimental to the function of
peritoneal cells. I am not convinced, therefore, of the necessity
of replacing this anion with bicarbonate in the dialysis solution.
The osmotic agent currently in use in the dialysis solution might
be toxic to mesothelial cells, and its absorption can produce
obesity as well as disorders in lipid metabolism. Some prelim-
inary accounts of a new osmotic agent, a hydrolysate from corn
starch, have reported promising results [107]. One of the
disadvantages in using this new compound however, is the
presence of very high levels of maltose in the serum.
DR. K. S. CHUGH (Postgraduate Medical Institute, Chandi-
garh, India): Is there any difference between the propensity of
mesothelial cells of the peritoneum to develop fibrosis in
patients who have been on chronic hemodialysis compared with
those who are initially started on CAPD?
DR. CHAIMOVITZ: That is a very interesting question. I am
not aware of any publications that describe peritoneal biopsies
when patients undergoing chronic hemodialysis are transferred
to CAPD treatment. I understand that you also are concerned
about the effect of chronic uremia per se on the morphology of
the peritoneal membrane. Dobbie described the morphology of
the peritoneal membrane in patients who had end-stage renal
disease before starting CAPD [19]. These biopsies revealed
minor changes such as cytoplasmic inclusions in the uremic
peritoneal mesothelial cells as compared to normal controls.
DR. NICHOLAS TOPLEY (Institute of Nephrology, University
of Wales, College of Medicine, Cardiff, Wales, United King-
dom): I'm interested in the time course of the fibrotic events:
Are the rapid, atypical events that occurred in this patient
related to the 33 months the patient already has been on CAPD?
That is, does the treatment itself sensitize the peritoneal mem-
brane to rapid sclerotic changes?
DR. CHAIMOVITZ: I agree absolutely that the rapid and
irreversible deterioration of the peritoneal function in this
patient is a rare clinical course for a patient on CAPD after
peritonitis. We can speculate that prior to the peritonitis, this
patient was already suffering from chronic damage to the
peritoneum, caused by exposure to the unphysiologic dialysis
solution. But this damage, if present, was not clinically evident
prior to the peritonitis. I do believe that long-term preservation
of membrane function should be a major goal of research
projects on the biocompatibiity of the dialysis solution.
DR. TOPLEY: Does treatment with vitamin D3 make the
peritoneal macrophages more mature? Can one measure sur-
face expression of markers of maturity? I believe that we know
from many previous studies that peritoneal macrophages be-
come increasingly immature with time on CAPD.
DR. CHAIM0vITz: That is a most interesting and challenging
question. Exposure to 1 ,25(OH)2D3 reduces the proliferation
and elicitates maturation of human tumor cell lines such as
HL6O and U937 leukemic cell into cells with monocyte/macro-
phage features [108, 109]. Thus, HL6O cells treated with
1 ,25(OH)2D3 acquire morphologic features and cell-surface
antigens of mature monocytes. Also, phagocytosis of S. aureus
by HL6O cells was markedly stimulated by treatment with
1 ,25(OH)2D3. Addition of 1 ,25(OH)2D3 at a concentration of
l0— M to culture of normal human marrow cells stimulated
myeloid stem cells to differentiate into monocytes and macro-
phages [109].
Let me return to your question. You are challenging us with
the possibility that the increasing immaturity of the pentoneal
macrophages, as the duration in CAPD lengthens, can be
explained by an abnormal metabolism of vitamin D in these
patients. Levels of 25(OH)D3 are low in CAPD because of
peritoneal loss of this metabolite. We now see more and more
patients in CAPD with very low plasma levels of I ,25(OH)2D3
because nephrologists are reluctant to adequately replace this
metabolite, fearing the development of hypercalcemia and low
bone turnover disease. Hence, many patients undergoing
CAPD are vitamin D deficient. The question remains whether
the immaturity of the peritoneal macrophages is related to
vitamin D deficiency; the answer is unclear and requires careful
examination. We should remember, however, that the in-vitro
differentiation-inducing effect of 1 ,25(OH)D2D3 requires supra-
physiologic concentration of this vitamin D metabohite.
DR. CHARLES R. KLEEMAN (Cedars-Sinai Medical Center,
Los Angeles, California): What is the effect of an osmotically
active substance other than glucose?
DR. CHAIMOvITz: Commercially available dialysis fluids uti-
lize glucose as the osmotic agent. Studies in vitro and in vivo
suggest that the high glucose content in the dialysis fluid inhibits
phagocytosis, bactericidal activity, chemiluminescence, and
LTB4 synthesis of peripheral blood neutrophils and peritoneal
macrophages [70, 76, 77]. The peritoneal absorption of glucose
also leads to metabolic disorders such as hyperlipidemia and
obesity. Alternative osmotic agents now being studied are
glycerol, amino-acid-based solutions, and glucose polymers.
Lately, clinical studies using a glucose polymer with a molec-
ular weight of 20,000 dalton have demonstrated significant
ultrafiltration in a prolonged dwell time of 12 hours in the
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peritoneal cavity [107]. All these alternative osmotic agents,
however, are still at the stage of clinical laboratory investiga-
tion, and no unequivocal results have proved that they will be
as effective as glucose.
DR. KLEEMAN: What happens to the phosphate content of
the mesothelial cells during dialysis?
DR. CHAIMOVITZ: I am not aware of any studies on phos-
phate concentration in mesothelial cells in patients on CAPD.
DR. KLEEMAN: What about content of TGFa and f3 and
PDGF in the fluid if any? Also, what is the effect of substances
like decorin, human proteoglycan, or antibodies to these cyto-
kines?
DR. CHAIM0vITz: Shimokado et al demonstrated that acti-
vated peritoneal macrophages secrete a mitogen for connective
tissue cells and that a large portion of this mitogenic activity is
due to a molecule similar to PDGF [30]. One can reasonably
assume that both PDGF and TGF/3 are significantly involved in
the pathogenesis of peritoneal fibrosis in CAPD. However,
more research is required to support this assumption. Yung et al
showed that the dialysis effluent from CAPD patients contains
substantial amounts of proteoglycans and that the predominant
glycosaminoglycan in the fluid is chondroitin/dermatan sulfate
[110]. Omentum-derived mesothelial cells secrete the proteo-
glycans decorin and biglycan [110, ill]. It is well known that
TGF/3 binds with high affinity to the core protein of these two
proteoglycans and that TGF bound to decorin will lose its
efficacy [112]. Since TGF up-regulates the synthesis of
decorin, this binding process can represent an important mod-
ulator of TGF/3 activity in the peritoneal cavity [113]. Again,
more research is required to define the physiologic significance
of proteoglycan in the peritoneal fluid.
DR. KLEEMAN: Is there an experimental model of this prob-
lem?
DR. CHAIM0vITz: Relatively few studies have been con-
ducted using animal models to clarify the effect of the dialysis
solution on the morphology, viability, and function of perito-
neal cells. But Bos and colleagues did investigate whether the
dialysis fluid could irritate the peritoneal cavity in rats [44].
Using studies of the pattern of endogenous peroxidase activity
of peritoneal macrophages, these researchers concluded that 24
hours of exposure to the dialysis solution produced the appear-
ance of an acute exudate in the peritoneal cavity of the animals.
I agree that much effort should be made in this particular area.
DR. RAYMOND T. KREDIET (Academic Medical Center,
Amsterdam, The Netherlands): The dialysate glucose concen-
trations measured during the peritonitis suggest that the func-
tion of the peritoneal membrane was not completely normal
previously, because generally inflammation produces a net loss
of ultrafiltration. This alteration necessitates the use of perito-
neal dialysis fluids with a higher glucose concentration.
DR. CHALMOVITZ: The patient's chart shows that during the
bout of peritonitis, he was still being treated with a dialysate
fluid containing 1.5% glucose. Despite a marked decrease in the
peritoneal ultrafiltration, his fluid balance was maintained by
increasing his urinary output via the admininstration of diuret-
ics. I agree with your comment that during an episode of
peritonitis, a severe defect in ultrafiltration commonly requires
the use of more hypertonic dialysis solutions. Experimental
data show that a high concentration of glucose might have a
detrimental effect on phagocyte function and a toxic effect on
mesothelial cells [22], so we must make every effort to avoid
using the 4.25% glucose dialysis fluid, especially when the
peritoneum is already damaged by microorganic invasion.
DR. KREDIET: The PET results indicate an isolated loss of net
ultrafiltration, since the DIDO glucose ratio remained essen-
tially within the normal range. This loss of ultrafiltration might
be explained by the presence of pockets in the peritoneal cavity
or by a loss of transcellular water transport. Rippe et al have
drawn attention to the possibility of the existence of ultra-small
transcellular pores that allow water transport without solute
transport [114]. Loss of cellular small pores would abolish the
decrease of dialysate sodium concentration normally seen dur-
ing the first hour of a PET test. My question is, did you measure
dialysate sodium? But also allow me a further comment. A low
creatinine clearance rate does not necessarily point to hypoper-
meability of the membrane, because the clearance of low-
molecular-weight solutes during CAPD dwells mainly depend
on dialysate flow rate and thus will decrease as the drained
volume decreases.
DR. CHAIMOVITZ: I agree that the marked decrease in the
peritoneal ultrafiltration of this patient contributed to the clini-
cal and biochemical evidence of underdialysis, since the PET
test did not reveal a defect in the peritoneal permeability to
solutes. You refer to the studies by Rippe et al, which sup-
ported the concept of a "three-pore" model of membrane
selectivity [114]. According to this model, the peritoneum can
be considered a membrane composed of a large number of small
pores (radius 40 to 60 A), a very small number of large pores
(radius 200 to 300 A), and a transcellular ultra-small pore of 4—S
A, which accounts for a substantial fluid flow driven by crys-
talloid osmotic forces such as glucose during CAPD. The
transcellular flow of fluid can explain the fall in the sodium
chloride concentration in the dialysate in the early phase of
dwell time. As I do not have available data on sodium concen-
tration in the dialysis effluent in the first 2 hours of dwell time,
I cannot confirm your interesting hypothesis that damage to the
ultra-small pores was involved in the peritoneal membrane
dysfunction in this particular patient.
DR. JAYSON RAPOPORT (Chief of Nephrology, Sheba Medical
Center, Tel-Hashomer, Israel): You described how the perito-
neal mesothelial cells can participate in the peritoneal inflam-
matory response by producing inflammatory cytokines. If these
cells acted as antigen-presenting cells, the peritoneal inflamma-
tory response might be greatly amplified. Do you have any
information on this point?
DR. CHAIMOVITZ: In our laboratory, Dr. Douvdevani col-
lected data showing that human omentum-derived mesothelial
cells expressed HLA-DR (unpublished data), and we are now in
the process of investigating the significance of this finding. Dr.
Douvdevani, would you like to comment on this matter?
DR. A. DOUVDEVANI (Nephrology Laboratory, Soroka Med-
ical Center): We found that human omentum-derived mesothe-
lial cells strongly express HLA-DR after stimulation with
y-interferon. The basal level of non-stimulated mesothelial cells
was very low. The expression of HLA-DR under inflammatory
conditions suggests that mesothelial cells serve as antigen-
presenting cells, thereby contributing to the immune response
of the peritoneum.
DR. Z. KORZETS (Physician-in-Charge, Peritoneal Dialysis,
Kfar Saba, Israel): Given the rapid equilibration of pH within
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the peritoneal cavity, how does that equate with continued
cytotoxicity due to low pH?
DR. CHAIM0vITz: We studied the cytosolic changes in the
peritoneal macrophages after acutely exposing them to perito-
neal dialysis solution titrated to pHs of 6.0, 6.5, and 7.0 by
adding NaOH. We tried to simulate the gradual alkalinization of
the pentoneal fluid during the first 30 minutes of dwell time.
Even after exposure to a dialysis solution titrated to a pH of 7.0,
the cytosolic pH dropped and stabilized at values of 6.7. Thus,
it would seem that in the first 30 minutes of dwell time, a
marked acidification of the peritoneal cells occurred, thereby
impairing their function.
DR. TOMASZ LIBEREK (Institute of Nephrology, University of
Wales School of Medicine, Cardff and Gdansk, Poland): I
think I can answer Dr. Korzets' question concerning intracel-
lular pH and pH equilibration during intraperitoneal dwell time
a bit further. We have done similar studies in neutrophils and
have seen a similar drop in their intracellular pH during
incubation in Dianeal, a low-pH, high-lactate fluid. But when
we transferred these cells to physiologic buffer, the intracellular
pH rose again, apparently back to nonnal. However, the
function of these neutrophils, at least as far as the respiratory
burst is concerned, was irreversibly damaged and did not
recover even as long as 4 hours later. I don't have a direct
answer to your question, but our experiments suggest that the
respiratory burst is affected at distal steps of intracellular signal
pathway. We stimulated cells treated with Dianeal 5.2 with
opsonized zymosan, PMA, FMLP, and calcium ionophore
A23 187. With none of these stimuli were we able to induce
respiratory burst activation as measured by chemiluminescence
response. With regard to the direct localization of this defect,
Rotstejn et al have shown that NADPH oxidase, the central
enzyme in respiratory burst activation, is sensitive to changes
in pH and that its activity is markedly inhibited at pH 5.0 [85].
DR. JOHN DONOHOE (Consultant Nephrologist, Beaumont!
Mater Hospitals, Dublin, Ireland): Are we any nearer to
developing "pH-friendly" peritoneal dialysate fluids, just as we
have moved away from acetate-based to bicarbonate-based
hemodialysis systems? Would lactate-free peritoneal dialysis
fluid be advantageous?
DR. CHAIM0vITz: As I already mentioned, no in-vitro data
support an inhibitory effect of lactate in phagocyte cell function
at a normal pH of 7.4 with concentrations such as those found
in the peritoneal dialysis solution (40 mEq!liter). As a first step
in improving the biocompatibiity of the dialysis solution, I
suggest using a dialysis solution containing a higher pH rather
than substituting lactate for bicarbonate.
DR. CHARLES VAN YPERSELE (Professor of Nephrology,
Université Catholique de Louvain, Brussels, Belgium): The
incidence of peritonitis has markedly decreased in recent years
because of technical improvements. Could you give us some
figures on the current incidence (that is, per 100 patient years)
of a loss of peritoneal surface as an impetus for treatment
modality change?
DR. CHAIM0Vrrz: I agree that following improvements in the
connecting systems for CAPD there has been a marked decline
in the incidence rate of peritonitis. However, much concern
remains as to how to preserve peritoneal function in patients on
long-term CAPD. Approximately 15% to 19% of patients un-
dergoing CAPD eventually have to change this mode of treat-
ment because of a loss of peritoneal function. Mactier recently
presented data showing ultrafiltration failure rates in patients on
CAPD: 3% of the patients on CAPD exhibited ultraffitration
failure after one year, 10% after 3 years, and 31% after 6 years
[115]. The majority of cases can be categorized in the type-I
ultrafiltration failure category, in which rapid absorption of
glucose in the dialysis fluid limits the net transcapillary ultrafil-
tration; only in a few patients was type-Il peritoneal dysfunc-
tion observed, which was due to a decrease in the peritoneal
membrane hydraulic permeability and/or peritoneal effective
surface area.
Da. VAN YPERSELE: Rarely, some patients develop an in-
creased ultrafiltration leading to their transfer to other treat-
ment modalities. Could you comment on this type of complica-
tion?
DR. CHAIMOVITZ: I have no personal experience with pa-
tients undergoing CAPD who had an increased ultrafiltration
that led to hypovolemia. I have followed patients on CAPD with
end-stage renal failure due to medullary cystic disease of the
kidneys and urinary salt losing. These patients were able to
maintain fluid balance by increasing their intake of water and
electrolytes.
DR. A. KAGAN (Consultant Nephrologist, Kaplan Hospital,
Rehovot, Israel): What is the role of humoral factors such as
IgG and lysozyme in the host defense mechanism in CAPD
patients? We have reported that the level of lysozyme in the
peritoneal fluid of CAPD patients is high [116].
DR. CHAIMOVITZ: Humoral opsonizing factors such as IgG
and C3 facilitate phagocytosis by coating microorganisms. The
concentration of these opsonines in the dialysate was found to
be 40 to 50 times lower than in the serum [117]. However, the
relationship between the low peritoneal opsonizing capacity in
CAPD and the occurrence of peritonitis is not unanimously
accepted. Disagreement also exists among investigators regard-
ing the significance of the low concentration of fibronectin in the
dialysate and the frequency of peritonitis. I am familiar with
your paper that demonstrated lysozyme activity in the perito-
neal effluent of CAPD patients [116]. However, the meaning of
this finding deserves further investigation.
DR. JACOB GREEN (Cedars Sinai Hospital, Los Angeles,
California): Was there any difference between Dianeal and
normal salt solution in the macrophages' ability to synthesize
1 ,25(OH)2D3?
DR. CHAIMOVITZ: That is an important issue currently being
investigated by Dr. Shany in our laboratories. As you know,
there are some controversial results regarding the suppressor
effect of acidosis on the renal conversion of 25(OH)D3 to
l,25(OH)2D3 [118]. The likelihood exists that the cytosolic
acidification of the peritoneal macrophages, which occurs after
exposure to the dialysis solution, limits the synthesis of
1 ,25(OH)2D3 to these cells. We are in the process of studying
this possibility.
Reprint requests to Dr. C. Chaimovitz, Head, Department of Neph-
rology, Soroka Medical Center of Kupat Holim, P.O. Box 151, Beer-
Sheva, 84101, Israel
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